कंपनी का अवलोकन
Alphatec Holdings, Inc. operates as a medical technology company focused on designing, developing, and advancing technologies for the surgical treatment of spinal disorders across the United States and international markets. The firm manufactures and distributes a comprehensive range of products including implants, surgical instruments, imaging equipment, and spare parts to support these specialized procedures. This entity functions within the Healthcare sector, specifically the Medical Devices industry, positioning it as a provider of critical infrastructure for orthopedic surgery. The company's scale is defined by a market capitalization of $1.68 billion, an annual revenue of $764.16 million, and a workforce of 913 employees. These valuation and revenue figures indicate that Alphatec holds a significant position in a niche market, commanding a substantial market cap relative to its revenue stream, which suggests high valuation multiples often associated with technology-driven healthcare firms. The substantial cash reserves of $160.81 million further contextualize its operational liquidity and capacity to fund ongoing research and development without immediate reliance on external financing.
वित्तीय स्वास्थ्य
The company reported a total revenue of $764.16 million over the trailing twelve months, yet it recorded a net income of -$143.358 million and an EBITDA of $19.53 million. The significant disparity between the positive revenue figure and the negative net income reveals a cost structure where operating expenses and interest costs exceed operating earnings, resulting in a substantial loss before taxes and other non-operating items. Despite the accounting loss, the company generated positive free cash flow of $56.15 million, which indicates a degree of financial flexibility allowing the firm to meet obligations and potentially invest in assets despite reporting a net loss on an accrual basis. The margin profile shows a gross margin of 69.6%, reflecting high pricing power or low cost of goods sold typical in implantable device manufacturing, while the operating margin stands at -2.5% and the profit margin is -18.8%, highlighting substantial overhead burdens relative to sales. On the balance sheet, total debt of $596.09 million significantly outweighs cash reserves of $160.81 million, supported by a debt-to-equity ratio of 1654.48, which characterizes a highly leveraged financial structure. Liquidity is managed with a current ratio of 2.06, suggesting that short-term assets are more than twice the value of short-term liabilities, providing a buffer against immediate liquidity pressures. Return on Equity is -630.7% and Return on Assets is -4.6%, metrics that reveal that management has not yet generated positive returns on shareholder capital or total assets, likely due to the net loss position impacting the denominators in these efficiency ratios.
मूल्यांकन आकलन
Valuation metrics present a complex picture, with a trailing P/E ratio listed as N/A due to the negative earnings, while the forward P/E is 20.11, implying that the market expects earnings normalization in the upcoming fiscal periods to justify current share prices. The price-to-book ratio is 133.37, indicating that the market values the company at more than 133 times its book value, which suggests a high market premium likely driven by intangible assets, growth expectations, or proprietary technology rather than tangible net assets. Alternative valuation multiples such as the price-to-sales ratio of 2.19 and an EV/EBITDA of 109.31 further emphasize the premium investors are placing on the company's revenue generation and earnings power before interest, taxes, depreciation, and amortization. Price momentum is captured by a 52-week high of $23.29 and a 52-week low of $8.81, where the current trading price sits within this range, reflecting recent volatility and market sentiment shifts over the past year. The stock exhibits a beta of 1.12, meaning its price volatility is 12% higher than the broader market, indicating that the security is more sensitive to overall market movements than a standard benchmark index.
Growth & Income
Revenue growth stands at 20.4% year-over-year, while earnings growth is N/A due to the reported net loss, illustrating that top-line expansion is currently outpacing bottom-line profitability as the company scales operations. Since the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, all earnings are theoretically available for reinvestment into business growth rather than distribution to shareholders. The absence of a dividend policy aligns with the company's lifecycle stage, where capital is typically retained to fund the high capital expenditures required for medical device manufacturing and R&D. The overall growth and income profile is defined by robust double-digit revenue expansion and a complete reinvestment of cash flows, rather than providing current income to investors through dividends.